Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,700,212
  • Shares Outstanding, K 3,929,696
  • Annual Sales, $ 50,438 M
  • Annual Income, $ -2,762 M
  • EBIT $ -1,875 M
  • EBITDA $ 11,507 M
  • 60-Month Beta 1.02
  • Price/Sales 0.50
  • Price/Cash Flow 1.42
  • Price/Book 0.74
  • Price/Earnings ttm 4.64
  • Earnings Per Share ttm 1.37
  • Most Recent Earnings $0.28 on 03/05/25
  • Next Earnings Date 03/04/25
  • Annual Dividend & Yield 0.02 (0.34%)
  • Most Recent Dividend 0.022 on 04/29/24
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.48
  • Number of Estimates 2
  • High Estimate 0.59
  • Low Estimate 0.38
  • Prior Year 0.77
  • Growth Rate Est. (year over year) -37.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.5400 +22.38%
on 02/19/25
6.8300 -0.73%
on 03/18/25
+1.0600 (+18.53%)
since 02/18/25
3-Month
4.7900 +41.54%
on 12/24/24
6.8300 -0.73%
on 03/18/25
+1.8600 (+37.80%)
since 12/18/24
52-Week
4.7900 +41.54%
on 12/24/24
8.5800 -20.98%
on 09/30/24
-0.3200 (-4.51%)
since 03/18/24

Most Recent Stories

More News
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More

This week, Bayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm Gubra for an amylin-targeting obesity treatment, which marked the...

BAYRY : 6.7950 (+3.90%)
NVO : 80.71 (+0.70%)
JNJ : 163.77 (+0.57%)
ABBV : 213.00 (-0.69%)
RHHBY : 43.9900 (-0.57%)
Bayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia Sales

Bayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the Zacks Consensus Estimates. The company reported earnings of 50 cents per ADR...

BAYRY : 6.7950 (+3.90%)
JNJ : 163.77 (+0.57%)
REGN : 669.89 (-1.26%)
Is This Beaten-Down Dividend Stock a Buy for Its Almost 7% Yield?

FMC’s dividend yield has surged to almost 7% after last week’s crash. However, risk-averse investors should give this stock a pass given the uncertainty over its future dividend payouts.

BAYRY : 6.7950 (+3.90%)
$SPX : 5,617.62 (-1.01%)
INTC : 26.05 (+1.40%)
NKE : 72.85 (-1.15%)
FMC : 42.66 (-0.05%)
DIS : 98.65 (-0.71%)
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the year-ago...

BAYRY : 6.7950 (+3.90%)
REGN : 669.89 (-1.26%)
RHHBY : 43.9900 (-0.57%)
SNY : 58.96 (+0.07%)
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference.Shares of the company moved up in pre-market trading on Jan. 14.Shares of...

BAYRY : 6.7950 (+3.90%)
REGN : 669.89 (-1.26%)
RHHBY : 43.9900 (-0.57%)
SNY : 58.96 (+0.07%)
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%.The stock has underperformed the sector and the S&P 500 Index during...

BAYRY : 6.7950 (+3.90%)
REGN : 669.89 (-1.26%)
RHHBY : 43.9900 (-0.57%)
AMGN : 316.33 (-0.26%)
SNY : 58.96 (+0.07%)
Is This Biotech Stock With 150% Upside a Buy Now?

The high price estimate for BridgeBio Pharma suggests potential upside of 150% in 2025.

BAYRY : 6.7950 (+3.90%)
AZN : 77.07 (-0.39%)
$SPX : 5,617.62 (-1.01%)
BBIO : 32.32 (-2.09%)
PFE : 26.23 (+0.69%)
Regeneron Down 15.5% Year to Date: How to Play the Stock?

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during...

BAYRY : 6.7950 (+3.90%)
REGN : 669.89 (-1.26%)
RHHBY : 43.9900 (-0.57%)
SNY : 58.96 (+0.07%)
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug

Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has started.COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart...

BAYRY : 6.7950 (+3.90%)
CYTK : 43.50 (-3.14%)
CSTL : 19.95 (-0.40%)
SPRO : 0.7700 (-0.12%)
FDA Accepts Cytokinetics' Application for Cardiovascular Drug

Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten.Aficamten is a next-in-class cardiac myosin inhibitor....

BAYRY : 6.7950 (+3.90%)
CYTK : 43.50 (-3.14%)
CSTL : 19.95 (-0.40%)
SPRO : 0.7700 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 6.6533
2nd Resistance Point 6.6067
1st Resistance Point 6.5733
Last Price 6.7950
1st Support Level 6.4933
2nd Support Level 6.4467
3rd Support Level 6.4133

See More

52-Week High 8.5800
Fibonacci 61.8% 7.1322
Last Price 6.7950
Fibonacci 50% 6.6850
Fibonacci 38.2% 6.2378
52-Week Low 4.7900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar